Takeda's hopes for its first-in-class Aurora kinase inhibitor now rest on Phase II studies in lung cancer after the company pulled the plug on its Phase III trial in a rare form of lymphoma.
The Phase III study of Takeda's oral Aurora A kinase inhibitor alisertib in relapsed/refractory peripheral T-cell lymphoma (PTCL) was suspended after a pre-specified interim analysis showed it was unlikely to beat standard of care for progression-free survival, the primary endpoint
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?